2026 Update: PSDS & IETF closed. AIA gives 100% year-one relief on solar. 2026 active stack still delivers 40–60% effective subsidy. See 2026 grants →

UK pharma solar — May 2026

Solar for UK pharmaceutical manufacturing — funding routes and GMP-compliant delivery.

UK pharma manufacturing is among the most electricity-intensive industrial sectors. With no open Scottish IETF call since March 2025 and the Annual Investment Allowance permanent, multi-MWp pharma solar projects continue to deliver 4-6 year payback alongside critical resilience benefits.

Independent
4.5yr
Avg Payback
Always check your installer is MCS-certified

UK pharma manufacturing — exceptional solar economics with operational complications

UK pharmaceutical manufacturing has substantial decarbonisation pressure and unusually strong solar economics. Three structural drivers: (1) electricity demand is exceptional — purification, cleanroom HVAC, sterilisation and cold chain all require continuous high electricity loads; (2) operational continuity is 24/7, producing self-consumption rates of 85-95% on properly sized PV systems; (3) major UK pharma manufacturers have public net zero commitments backed by substantial capital programmes.

The complications are operational rather than economic. GMP compliance affects how PV install can be sequenced around production schedules. Cleanroom HVAC plant on the roof reduces useful unobstructed area for PV. And the cold chain criticality of many pharma processes means solar plus battery integration becomes a resilience question, not just an economic one.

The 2026 funding stack for UK pharma manufacturing

Scottish pharma (GSK Montrose, Piramal Grangemouth, others)

SIETF is closed: its last call closed in March 2025 and no new call has been announced. Up to 30% of capex (50% for deep decarbonisation including process electrification). Stack with the Annual Investment Allowance on net of grant + SEG.

English pharma (the majority of UK pharma)

English IETF closed for new applications. Active stack: AIA + SEG + PPA + (for sites in eligible Mayoral Authority areas) Local Growth Fund. PPA is the dominant route at multi-MWp scale because of operator covenant strength.

Welsh and NI pharma

Welsh Industrial Decarbonisation (Welsh sites) and Invest NI Capital Grants (Almac, Norbrook). Both have funded several pharma manufacturing decarbonisation packages since 2022.

Major UK pharma manufacturers and their solar programmes

GSK

UK manufacturing sites include Barnard Castle (antibiotics, respiratory), Ulverston (vaccines), Ware (consumer healthcare), Worthing (oncology), Stevenage (R&D + commercial), Montrose (Scotland — APIs). Multi-site PV programme since 2022, funded through internal capital (the IETF never funded solar PV and closed in July 2025). Multiple sites with multi-MWp solar deployment.

AstraZeneca

UK manufacturing at Macclesfield (oncology, cardiovascular), Luton (respiratory), Speke (small molecules). New Cambridge Discovery Centre opened with substantial integrated PV. Multi-site UK PV programme.

Pfizer

Sandwich (UK R&D and commercial). Solar deployment progressing under Pfizer global net zero commitment.

Eli Lilly

Speke (one of the largest UK pharma manufacturing sites — cytostatic injectables, insulin). PV deployment since 2022 funded from internal capital; solar PV was never an eligible IETF technology.

Almac Group (Northern Ireland)

Craigavon (NI) and Edinburgh (Scotland) sites. Solar at both. Decarbonisation projects funded under the NI programme and SIETF (now closed); the solar was not SIETF-funded, as solar PV was never SIETF-eligible.

UK pharma supply chain

Tier-2 and tier-3 pharma suppliers — API manufacturers (Cambrex, Sterling Pharma, Dextra Labs), packaging specialists, cold-chain logistics, formulation specialists. Often more accessible for active 2026 funding routes than the major branded manufacturers (less internal capital availability, more grant dependency).

Worked example — UK pharma manufacturing site 2026

A typical UK pharma manufacturing site (formulation, packaging, distribution): 12 GWh/year electricity demand, 22,000 m² rooftop:

  • System size: 1.8 MWp rooftop + 800kWh battery (cold-chain resilience)
  • Headline capex: £1.32m PV + £360k battery = £1.68m total
  • Annual Investment Allowance on full capex: £420,000 (25%)
  • Net cost: £1.26m
  • Annual savings (electricity displacement + SEG export): £385,000
  • Payback: 3.3 years
  • Battery resilience: 4-6 hours of cold-chain backup at typical refrigeration load

GMP compliance and install sequencing

Pharma manufacturing PV installs need GMP-aware contracting. Specifically:

  • Roof access scheduling around production batch cycles
  • Risk assessment for any ingress points near GMP areas
  • Validation requirements for changes to electrical infrastructure feeding production areas
  • Cleanroom HVAC plant — solar mounting must not interfere with airflow, particulate filtration access, or exhaust paths
  • Audit trail documentation for the install

We work with MCS-certified installers who have GMP delivery experience — the bench is small but each major UK pharma manufacturing region has at least one capable EPC.

Related sector pages

Pharma manufacturing solar FAQs

Are UK pharmaceutical manufacturers eligible for solar grants in 2026?
Scottish pharma manufacturers were SIETF-eligible, but SIETF closed in March 2025 and never funded solar PV. English pharma sites were IETF-eligible for process efficiency and decarbonisation, but the IETF never funded solar PV and closed in July 2025 with no successor, so pharma solar is priced on the AIA then the 50% special-rate FYA, or a PPA. Active English pharma routes: the Annual Investment Allowance (25% via tax), PPAs at scale. Welsh pharma uses Welsh Industrial Decarbonisation; Northern Irish pharma (Almac, Norbrook) uses Invest NI Capital Grants.
What size solar PV does pharma manufacturing need?
Pharma manufacturing electricity demand is exceptional — purification, cleanroom HVAC (HEPA filtration runs 24/7), refrigeration for raw materials and finished product, sterilisation. A typical UK pharma manufacturing site uses 5-30 GWh/year. On-site solar PV typically targets 5-15% of annual demand because of roof area constraints and cleanroom plant on the roof. Typical pharma solar projects 500kWp-3MWp + ground-mount where adjacent land is available.
Why are pharma manufacturing sites unusual for solar?
Three specific complications. (1) GMP compliance — pharma manufacturing is regulated under MHRA / FDA / EMA Good Manufacturing Practice; any infrastructure work near production areas requires GMP-aware contracting and validation. (2) Cleanroom plant on roof — pharma manufacturing roofs typically host substantial HVAC, particulate filtration and process plant, reducing useful unobstructed roof area for PV. (3) Cold chain criticality — many pharma processes have strict temperature stability requirements; solar power continuity through grid disturbances becomes a UPS / resilience question, not just an economic one.
Have major UK pharma manufacturers deployed solar?
Yes — extensively. GSK has solar at multiple UK manufacturing sites including Barnard Castle, Ulverston and Ware. AstraZeneca runs a major UK PV programme across Macclesfield, Luton, Speke and the new Cambridge Discovery Centre. Pfizer has Sandwich PV. Eli Lilly Speke (one of the largest UK pharma manufacturing sites) has been progressing PV since 2022. Almac Group (NI) has solar at its Craigavon and Edinburgh sites. The UK Tier-1 pharma manufacturer ecosystem is several years into multi-MWp PV deployment.
Can pharma supply chain access solar funding?
Yes — and the supply chain is often the more accessible part of the funding stack. Pharma suppliers often met IETF thresholds while it ran, but IETF closed in July 2025 and SIETF’s last call closed in March 2025, so neither can be applied for now. The English pharma supply chain (post-IETF closure) uses AIA + PPA for solar deployment.
How does battery storage fit pharma manufacturing solar?
Strong fit. Pharma manufacturing has continuous high electricity demand (24/7 cleanroom HVAC + cold chain refrigeration), so battery captures generation that would otherwise export and uses it overnight. Adding 200-500kWh battery to a 500-1MWp PV system typically lifts self-consumption from 80% to 92-95%. Battery is also AIA-eligible. For pharma sites with critical cold chain, solar+battery+UPS integration creates a resilience asset alongside the economic case.
Free funding review

See which grants your business qualifies for — free 20-minute funding review.

Tell us your sector, roof size and energy spend. We reply by email with a shortlist of grants and the realistic capex you can expect to recover.

Start Funding Review

No obligation. We don't charge for grant scoping.

Funding by asset class

The allowance depends on the asset, and most pages on this topic get it the wrong way round. Solar PV is special-rate expenditure (HMRC Capital Allowances Manual CA22335), so the 100% year-one route is the Annual Investment Allowance — Full Expensing is a main-rate measure and does not reach it. Battery storage, EV charging and heat pumps are Heat pumps for space or water heating are special-rate: AIA, then the 50% FYA. Standalone batteries are probably main-rate (full expensing for companies), but HMRC has no specific guidance; confirm with your adviser.

Free funding review

Find out which 2026 schemes your site actually qualifies for

What you get
  • 1. A short written funding note naming every scheme your site qualifies for in 2026 — and the ones it does not.
  • 2. Indicative system size and a capex band for your roof.
  • 3. Year-one tax treatment per asset in £ — solar is special-rate expenditure, so the route is the Annual Investment Allowance; heat pumps for building heating are also special-rate integral features, and standalone battery storage is probably main-rate plant (HMRC has no specific guidance, so confirm with your adviser). Most pages get this the wrong way round.
  • 4. Projected SEG export revenue at current rates.
  • 5. Any red-flag eligibility or DNO issues we can see up front.

Covers solar PV, battery storage, EV charging and commercial heat pumps — separately or as one bundled project. If your project is a heat pump or a battery rather than a roof, say so in the message box and the note is written against that asset instead.

What we will not do
  • · We do not pass your details to multiple installers.
  • · We do not run a lead auction, and your phone number is optional.
  • · No marketing lists, no unsolicited calls.
  • · We are an independent funding information service — not an installer.

Five questions. They are the eligibility test itself — scheme eligibility in 2026 turns on sector, tenure, site size and spend, so we cannot shortlist anything without them.

We reply from funding@commercialsolargrants.co.uk. A phone number is not required.

Explore this guide cluster

Commercial solar by industry

Sector-specific solar economics — roof inventory, demand profile and the grants that apply to your industry.

Pillar guideSolar by industry & sectorEvery sector we cover, in one place. See all 29 sectors